文献速递认知障碍与谵妄老年综合评估

长效鼻内胰岛素治疗谵妄:一项随机临床试验

Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial.
PubMed 文献 · Age Ageing · 2025-01-01

意向性分析纳入97例,主要结局谵妄持续时间无显著差异(HR 0.7,95%CI 0.43-1.15;P=0.16),但急性住院时间显著缩短(HR 0.56,95%CI 0.35-0.89;

要点

  • 鼻内长效胰岛素未显著缩短总体谵妄持续时间,但急性住院时间显著缩短。
  • 预设亚组分析提示≤88岁患者谵妄持续时间缩短,>88岁患者未见差异。
  • 鼻内胰岛素耐受性良好,86%参与者依从性≥80%剂量。

核心结论

  • 鼻内长效胰岛素未显著缩短总体谵妄持续时间,但显著缩短急性住院时间,并观察到年龄相关效应,值得进一步研究。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照试验,在三级医院两个老年医学科病房开展。
  • 意向性分析纳入97例,鼻内胰岛素组48例、对照组49例,平均(SD)年龄87.6(7.0)岁,63%为女性。

主要发现

  • 中位谵妄持续时间(天,IQR)鼻内胰岛素组为4.8(2.9,9.2),对照组为6.8(4.0,9.8),HR 0.7(95%CI 0.43-1.15;P=0.16)。
  • 其他次要结局(谵妄严重程度、抗精神病药使用、医院并发症和死亡率)未见显著差异。

关键数值与推荐

  • 鼻内长效胰岛素用法为20 IU每日两次,直至谵妄缓解、出院或符合预设标准的干预无效。
  • 主要结局谵妄持续时间采用混淆评估法(CAM)每日评估。
  • 86%的参与者依从性良好,即≥80%的剂量被完成。

临床怎么用

  • 目前证据不支持将鼻内长效胰岛素作为谵妄的常规治疗,但缩短急性住院时间的信号值得关注。
  • 对≤88岁的谵妄患者,鼻内胰岛素可能带来谵妄持续时间缩短的获益,但需进一步研究验证。
  • 鼻内胰岛素耐受性良好,可作为未来研究中的候选干预措施。

局限性

  • 单中心研究,样本量较小(意向性分析97例),结果需外部验证。
  • 主要结局未达统计学显著,年龄亚组分析为预设但属探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delirium affects up to 25% of hospitalised older patients; however, there are no effective pharmacological treatments. Accumulating evidence of brain insulin resistance and altered cerebral glucose metabolism during delirium present a promising therapeutic target. OBJECTIVE: To assess the safety and efficacy of intranasal insulin in the treatment of delirium. DESIGN: Single-centre, randomised, double-blind, placebo-controlled trial. SETTING: Two geriatric medicine wards in a tertiary hospital. PARTICIPANTS: 100 patients aged over 64 years presenting to hospital and admitted under geriatric medicine with delirium. INTERVENTIONS: Participants were randomised in a 1:1 ratio to receive 20 IU of long-acting insulin or placebo intranasally twice daily until delirium resolution, hospital discharge or intervention futility defined by prespecified criteria. MAIN OUTCOME: The primary outcome was delirium duration, assessed daily using the Confusion Assessment Method. Secondary outcomes included acute length of stay (LOS), delirium severity, antipsychotic use, hospital complications and mortality. RESULTS: The intention-to-treat analysis included 97 participants [intranasal insulin n = 48, control n = 49; mean (SD) age, 87.6 (7.0) years; 63% female]. Baseline characteristics were similar between groups. Median delirium duration [days (IQR)] was 4.8 [2.9, 9.2] for intranasal insulin and 6.8 [4.0, 9.8] for the control (HR 0.7, 95% CI 0.43-1.15; P = .16). Median acute LOS (days) was 7.9 [4.6, 14.5] for intranasal insulin and 12.9 [6.9, 16.8] for the control (HR 0.56, 0.35-0.89; P = .014). No significant differences were observed in other secondary outcomes. Intranasal insulin demonstrated favourable tolerability. Overall, 86% of the participants were compliant with the intervention (≥80% of doses). Prespecified subgroup analysis revealed an age-related response, with participants aged ≤88 years showing shorter delirium duration with intranasal insulin [n = 46; intranasal insulin: median 3.9 (IQR 2.9, 6.9) days vs control: 7.0 (4.7, 9.7); HR 0.34, 0.16-0.74; P = .006], whereas no difference was observed in participants aged >88 years [n = 51; intranasal insulin 5.4 (2.9, 11.1) vs control 4.9 (2.6, 12.9); HR 0.87, 0.39-1.94; P = .73]. CONCLUSION AND RELEVANCE: This is the first study of intranasal insulin for delirium treatment. The reduced LOS combined with the observed age-related effects warrants further investigation into the clinical potential of intranasal insulin in managing delirium in older patients. TRIAL REGISTRATION: ACTRN 12618000318280.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Nitchingham A, Close JCT, Harvey LA, et al. Long-acting intranasal insulin for the treatment of delirium-a randomised clinical trial. Age Ageing. 2025. PMID: 41091693. doi:10.1093/ageing/afaf276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。